Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.60 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.48 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762468 | 0.80 | PIK3CA (0.61) | PIK3CAMTORSMG1 | |
| SCHEMBL3765548 | 0.78 | PIK3CA (0.64) | PIK3CACREBBP | |
| SCHEMBL3755996 | 0.78 | PIK3CA (0.65) | PIK3CAGPR142 | |
| SCHEMBL3753031 | 0.77 | PIK3CA (0.80) | PIK3CAMTOR | |
| SCHEMBL3798993 | 0.77 | SMG1 (0.52) | SMG1GPR142CAMK2DIKBKBCHUK | |
| SCHEMBL3758088 | 0.77 | PIK3CA (0.75) | PIK3CAGPR142 | |
| SCHEMBL3755936 | 0.76 | PIK3CA (0.71) | PIK3CA | |
| SCHEMBL3754906 | 0.76 | PIK3CA (0.70) | PIK3CAMTOR | |
| SCHEMBL3756038 | 0.76 | PIK3CA (0.67) | PIK3CAGPR142 | |
| SCHEMBL3761137 | 0.76 | PIK3CA (0.67) | PIK3CAMTORGPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PIK3CA 16/4885MTOR 1/4885SMG1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.